PDF(Pubmed)
Abstract：
UNASSIGNED: The anti-inflammatory effect could be one of the mechanisms by which semaglutide reduces cardiovascular risk in patients with type 2 diabetes mellitus (T2DM) and/or obesity. Determining the anti-inflammatory effect of semaglutide was the objective of this systematic review and meta-analysis.
UNASSIGNED: This meta-analysis was performed according to the PRISMA guidelines. A literature search was performed to detect randomised clinical trials that have quantified the effect of semaglutide on C-reactive protein (CRP) levels compared to placebo or a control group (other glucose-lowering drugs). The primary outcome was CRP index (final CRP/basal CRP). A random-effects model was used.
UNASSIGNED: Thirteen randomised clinical trials were considered eligible (n = 26,131). Overall, semaglutide therapy was associated with lower CRP index values compared to the placebo group (SMD -0.56; 95% CI -0.69 to -0.43, I 2 92%) or the control group (SMD -0.45; 95% CI -0.68 to -0.23, I 2 82%).Such an association was similarly observed when different treatment regimens (subcutaneous vs. oral) or different populations (patients with or without T2DM) were analysed. The sensitivity analysis showed that the results were robust.
UNASSIGNED: The present meta-analysis demonstrated that the use of semaglutide was associated with a reduction in inflammation irrespective of the population evaluated or the treatment regimen used. These findings would explain one of the mechanisms by which semaglutide reduces cardiovascular events.
UNASSIGNED: PROSPERO [CRD42024500551].
UNASSIGNED: This meta-analysis was performed according to the PRISMA guidelines. A literature search was performed to detect randomised clinical trials that have quantified the effect of semaglutide on C-reactive protein (CRP) levels compared to placebo or a control group (other glucose-lowering drugs). The primary outcome was CRP index (final CRP/basal CRP). A random-effects model was used.
UNASSIGNED: Thirteen randomised clinical trials were considered eligible (n = 26,131). Overall, semaglutide therapy was associated with lower CRP index values compared to the placebo group (SMD -0.56; 95% CI -0.69 to -0.43, I 2 92%) or the control group (SMD -0.45; 95% CI -0.68 to -0.23, I 2 82%).Such an association was similarly observed when different treatment regimens (subcutaneous vs. oral) or different populations (patients with or without T2DM) were analysed. The sensitivity analysis showed that the results were robust.
UNASSIGNED: The present meta-analysis demonstrated that the use of semaglutide was associated with a reduction in inflammation irrespective of the population evaluated or the treatment regimen used. These findings would explain one of the mechanisms by which semaglutide reduces cardiovascular events.
UNASSIGNED: PROSPERO [CRD42024500551].
摘要：
■抗炎作用可能是司马鲁肽降低2型糖尿病（T2DM）和/或肥胖患者心血管风险的机制之一。本系统评价和荟萃分析的目的是确定司马鲁肽的抗炎作用。
■这项荟萃分析是根据PRISMA指南进行的。进行了文献检索以检测随机临床试验，这些试验量化了司马鲁肽与安慰剂组或对照组（其他降糖药）相比对C反应蛋白（CRP）水平的影响。主要结果是CRP指数（最终CRP/基础CRP）。使用了随机效应模型。
■13项随机临床试验被认为是合格的（n=26,131）。总的来说,与安慰剂组(SMD-0.56;95%CI-0.69~-0.43,I292%)或对照组(SMD-0.45;95%CI-0.68~-0.23,I282%)相比,司马鲁肽治疗的CRP指数值较低.当不同的治疗方案（皮下与口服）或不同人群（有或没有T2DM的患者）进行分析。敏感性分析表明，结果是稳健的。
■本荟萃分析表明，无论评估的人群或使用的治疗方案如何，司马鲁肽的使用都与炎症的减轻有关。这些发现将解释司马鲁肽减少心血管事件的机制之一。
■PROSPERO[CRD42024500551]。
■这项荟萃分析是根据PRISMA指南进行的。进行了文献检索以检测随机临床试验，这些试验量化了司马鲁肽与安慰剂组或对照组（其他降糖药）相比对C反应蛋白（CRP）水平的影响。主要结果是CRP指数（最终CRP/基础CRP）。使用了随机效应模型。
■13项随机临床试验被认为是合格的（n=26,131）。总的来说,与安慰剂组(SMD-0.56;95%CI-0.69~-0.43,I292%)或对照组(SMD-0.45;95%CI-0.68~-0.23,I282%)相比,司马鲁肽治疗的CRP指数值较低.当不同的治疗方案（皮下与口服）或不同人群（有或没有T2DM的患者）进行分析。敏感性分析表明，结果是稳健的。
■本荟萃分析表明，无论评估的人群或使用的治疗方案如何，司马鲁肽的使用都与炎症的减轻有关。这些发现将解释司马鲁肽减少心血管事件的机制之一。
■PROSPERO[CRD42024500551]。
